Myositis‐specific antibodies (MSAs)—including anti‐Mi‐2, anti‐melanoma differentiation‐associated protein 5 (MDA5), anti‐nuclear matrix protein 2, anti‐transcription intermediary factor 1 (TIF1)—have emerged as valuable biomarkers for the diagnosis and subclassification of DM [173]. This evidence concerns the gene TRIM24 and dermatomyositis.